PF-07328948

Phase 1Small molecule

Pfizer

PF-07328948 is one of 99 small molecule programs targeting Hepatic Impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic ImpairmentRecruiting

AdultCompleted

FunctionRecruiting

Hepatic ImpairmentPhase 1

Recruiting

AdultPhase 1

Completed

FunctionPhase 1

Recruiting

Competition

Competitive Landscape

127 competitors in Adult

#DrugCompanyPhaseTrials

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 2

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Myqorzo

CCytokinetics

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 2

1 7

Cabenuva

GSK

Phase 1

6 8

Skyclarys

Biogen

Phase 1

3 9

Sunlenca

Gilead

Phase 1

1 10

NM8074

NNovelMed Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hepatic Impairment

NCT07269301

Phase 1Recruiting

Function

NCT07315360

Clinical

Trials by Indication[1]

Adult3 trials

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT05807490·86 enrolled

A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06837259·26 enrolled

A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07455240·10 enrolled

Single Dose1 trial

A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05654181·20 enrolled

Function1 trial

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07315360·28 enrolled

Hepatic Impairment1 trial

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIRMENT

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07269301·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PF-07328948. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-07328948 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-07328948. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

PF-07328948

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Adult3 trials

Single Dose1 trial

Function1 trial

Hepatic Impairment1 trial

References

Drug Info

Quick Facts

Related News